Loading…

HER2-Specific Peptide Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study

This study aims to prepare a novel breast cancer-targeted micelle-based nanocarrier, which is stable in circulation, allowing intracellular drug release, and to investigate its cytotoxicity, apoptosis, and cytostatic effects, in vitro. The shell part of the micelle is composed of zwitterionic sulfob...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2023-02, Vol.15 (3)
Main Authors: Bayram, Nazende Nur, Ulu, Gizem Tuğçe, Abdulhadi, Nusaibah Abdulsalam, Gürdap, Seda, İşoğlu, İsmail Alper, Baran, Yusuf, İşoğlu, Sevil Dinçer
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 3
container_start_page
container_title Pharmaceutics
container_volume 15
creator Bayram, Nazende Nur
Ulu, Gizem Tuğçe
Abdulhadi, Nusaibah Abdulsalam
Gürdap, Seda
İşoğlu, İsmail Alper
Baran, Yusuf
İşoğlu, Sevil Dinçer
description This study aims to prepare a novel breast cancer-targeted micelle-based nanocarrier, which is stable in circulation, allowing intracellular drug release, and to investigate its cytotoxicity, apoptosis, and cytostatic effects, in vitro. The shell part of the micelle is composed of zwitterionic sulfobetaine ((N-3-sulfopropyl-N,N-dimethylamonium)ethyl methacrylate), while the core part is formed by another block, consisting of AEMA (2-aminoethyl methacrylamide), DEGMA (di(ethylene glycol) methyl ether methacrylate), and a vinyl-functionalized, acid-sensitive cross-linker. Following this, a targeting agent (peptide (LTVSPWY) and antibody (Herceptin[sup.®] )), in varying amounts, were coupled to the micelles, and they were characterized by [sup.1] H NMR, FTIR (Fourier-transform infrared spectroscopy), Zetasizer, BCA protein assay, and fluorescence spectrophotometer. The cytotoxic, cytostatic, apoptotic, and genotoxic effects of doxorubicin-loaded micelles were investigated on SKBR-3 (human epidermal growth factor receptor 2 (HER2)-positive) and MCF10-A (HER2-negative). According to the results, peptide-carrying micelles showed a higher targeting efficiency and better cytostatic, apoptotic, and genotoxic activities than antibody-carrying and non-targeted micelles. Also, micelles masked the toxicity of naked DOX on healthy cells. In conclusion, this nanocarrier system has great potential to be used in different drug-targeting strategies, by changing targeting agents and drugs.
doi_str_mv 10.3390/pharmaceutics15030733
format article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A743769713</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743769713</galeid><sourcerecordid>A743769713</sourcerecordid><originalsourceid>FETCH-LOGICAL-g673-a50830955072ebd71284e764430dd96cc5aa4fbaebd202ca3cd36d9d4141a9d13</originalsourceid><addsrcrecordid>eNptjE9LAzEQxYMoWGo_ghDwvDXZyW4ab3WprVBRbO91mszW6P4j2Qp-exf00INvDvN485vH2LUUUwAjbrt3DDVaOvbeRpkJEBrgjI2kMSZRJoXzE3_JJjF-iEEAcgZmxN5Wi9c02XRkfektf6Gu9474FsOBenK8aAPxIrQxJmvffA7Jk7dUVRR52QZ-HwhjzwtsLIU7Ph_4usOAvf8ivumP7vuKXZRYRZr87THbPiy2xSpZPy8fi_k6OeQaEszEDITJMqFT2jst05kinSsFwjmTW5shqnKPwy0VqUWwDnJnnJJKonESxuzmt_aAFe18U7Z9QFv7aHdzrUDnRksYqOk_1DCOam_bhko_5CcPP56AaOw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>HER2-Specific Peptide Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study</title><source>Publicly Available Content Database</source><source>PubMed Central (Training)</source><creator>Bayram, Nazende Nur ; Ulu, Gizem Tuğçe ; Abdulhadi, Nusaibah Abdulsalam ; Gürdap, Seda ; İşoğlu, İsmail Alper ; Baran, Yusuf ; İşoğlu, Sevil Dinçer</creator><creatorcontrib>Bayram, Nazende Nur ; Ulu, Gizem Tuğçe ; Abdulhadi, Nusaibah Abdulsalam ; Gürdap, Seda ; İşoğlu, İsmail Alper ; Baran, Yusuf ; İşoğlu, Sevil Dinçer</creatorcontrib><description>This study aims to prepare a novel breast cancer-targeted micelle-based nanocarrier, which is stable in circulation, allowing intracellular drug release, and to investigate its cytotoxicity, apoptosis, and cytostatic effects, in vitro. The shell part of the micelle is composed of zwitterionic sulfobetaine ((N-3-sulfopropyl-N,N-dimethylamonium)ethyl methacrylate), while the core part is formed by another block, consisting of AEMA (2-aminoethyl methacrylamide), DEGMA (di(ethylene glycol) methyl ether methacrylate), and a vinyl-functionalized, acid-sensitive cross-linker. Following this, a targeting agent (peptide (LTVSPWY) and antibody (Herceptin[sup.®] )), in varying amounts, were coupled to the micelles, and they were characterized by [sup.1] H NMR, FTIR (Fourier-transform infrared spectroscopy), Zetasizer, BCA protein assay, and fluorescence spectrophotometer. The cytotoxic, cytostatic, apoptotic, and genotoxic effects of doxorubicin-loaded micelles were investigated on SKBR-3 (human epidermal growth factor receptor 2 (HER2)-positive) and MCF10-A (HER2-negative). According to the results, peptide-carrying micelles showed a higher targeting efficiency and better cytostatic, apoptotic, and genotoxic activities than antibody-carrying and non-targeted micelles. Also, micelles masked the toxicity of naked DOX on healthy cells. In conclusion, this nanocarrier system has great potential to be used in different drug-targeting strategies, by changing targeting agents and drugs.</description><identifier>ISSN: 1999-4923</identifier><identifier>EISSN: 1999-4923</identifier><identifier>DOI: 10.3390/pharmaceutics15030733</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Antibodies ; Comparative analysis ; Drug delivery systems ; Drugs ; Identification and classification ; Materials ; Micelles ; Peptides ; Vehicles ; Viral antibodies</subject><ispartof>Pharmaceutics, 2023-02, Vol.15 (3)</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Bayram, Nazende Nur</creatorcontrib><creatorcontrib>Ulu, Gizem Tuğçe</creatorcontrib><creatorcontrib>Abdulhadi, Nusaibah Abdulsalam</creatorcontrib><creatorcontrib>Gürdap, Seda</creatorcontrib><creatorcontrib>İşoğlu, İsmail Alper</creatorcontrib><creatorcontrib>Baran, Yusuf</creatorcontrib><creatorcontrib>İşoğlu, Sevil Dinçer</creatorcontrib><title>HER2-Specific Peptide Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study</title><title>Pharmaceutics</title><description>This study aims to prepare a novel breast cancer-targeted micelle-based nanocarrier, which is stable in circulation, allowing intracellular drug release, and to investigate its cytotoxicity, apoptosis, and cytostatic effects, in vitro. The shell part of the micelle is composed of zwitterionic sulfobetaine ((N-3-sulfopropyl-N,N-dimethylamonium)ethyl methacrylate), while the core part is formed by another block, consisting of AEMA (2-aminoethyl methacrylamide), DEGMA (di(ethylene glycol) methyl ether methacrylate), and a vinyl-functionalized, acid-sensitive cross-linker. Following this, a targeting agent (peptide (LTVSPWY) and antibody (Herceptin[sup.®] )), in varying amounts, were coupled to the micelles, and they were characterized by [sup.1] H NMR, FTIR (Fourier-transform infrared spectroscopy), Zetasizer, BCA protein assay, and fluorescence spectrophotometer. The cytotoxic, cytostatic, apoptotic, and genotoxic effects of doxorubicin-loaded micelles were investigated on SKBR-3 (human epidermal growth factor receptor 2 (HER2)-positive) and MCF10-A (HER2-negative). According to the results, peptide-carrying micelles showed a higher targeting efficiency and better cytostatic, apoptotic, and genotoxic activities than antibody-carrying and non-targeted micelles. Also, micelles masked the toxicity of naked DOX on healthy cells. In conclusion, this nanocarrier system has great potential to be used in different drug-targeting strategies, by changing targeting agents and drugs.</description><subject>Antibodies</subject><subject>Comparative analysis</subject><subject>Drug delivery systems</subject><subject>Drugs</subject><subject>Identification and classification</subject><subject>Materials</subject><subject>Micelles</subject><subject>Peptides</subject><subject>Vehicles</subject><subject>Viral antibodies</subject><issn>1999-4923</issn><issn>1999-4923</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptjE9LAzEQxYMoWGo_ghDwvDXZyW4ab3WprVBRbO91mszW6P4j2Qp-exf00INvDvN485vH2LUUUwAjbrt3DDVaOvbeRpkJEBrgjI2kMSZRJoXzE3_JJjF-iEEAcgZmxN5Wi9c02XRkfektf6Gu9474FsOBenK8aAPxIrQxJmvffA7Jk7dUVRR52QZ-HwhjzwtsLIU7Ph_4usOAvf8ivumP7vuKXZRYRZr87THbPiy2xSpZPy8fi_k6OeQaEszEDITJMqFT2jst05kinSsFwjmTW5shqnKPwy0VqUWwDnJnnJJKonESxuzmt_aAFe18U7Z9QFv7aHdzrUDnRksYqOk_1DCOam_bhko_5CcPP56AaOw</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Bayram, Nazende Nur</creator><creator>Ulu, Gizem Tuğçe</creator><creator>Abdulhadi, Nusaibah Abdulsalam</creator><creator>Gürdap, Seda</creator><creator>İşoğlu, İsmail Alper</creator><creator>Baran, Yusuf</creator><creator>İşoğlu, Sevil Dinçer</creator><general>MDPI AG</general><scope/></search><sort><creationdate>20230201</creationdate><title>HER2-Specific Peptide Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study</title><author>Bayram, Nazende Nur ; Ulu, Gizem Tuğçe ; Abdulhadi, Nusaibah Abdulsalam ; Gürdap, Seda ; İşoğlu, İsmail Alper ; Baran, Yusuf ; İşoğlu, Sevil Dinçer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g673-a50830955072ebd71284e764430dd96cc5aa4fbaebd202ca3cd36d9d4141a9d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies</topic><topic>Comparative analysis</topic><topic>Drug delivery systems</topic><topic>Drugs</topic><topic>Identification and classification</topic><topic>Materials</topic><topic>Micelles</topic><topic>Peptides</topic><topic>Vehicles</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bayram, Nazende Nur</creatorcontrib><creatorcontrib>Ulu, Gizem Tuğçe</creatorcontrib><creatorcontrib>Abdulhadi, Nusaibah Abdulsalam</creatorcontrib><creatorcontrib>Gürdap, Seda</creatorcontrib><creatorcontrib>İşoğlu, İsmail Alper</creatorcontrib><creatorcontrib>Baran, Yusuf</creatorcontrib><creatorcontrib>İşoğlu, Sevil Dinçer</creatorcontrib><jtitle>Pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bayram, Nazende Nur</au><au>Ulu, Gizem Tuğçe</au><au>Abdulhadi, Nusaibah Abdulsalam</au><au>Gürdap, Seda</au><au>İşoğlu, İsmail Alper</au><au>Baran, Yusuf</au><au>İşoğlu, Sevil Dinçer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HER2-Specific Peptide Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study</atitle><jtitle>Pharmaceutics</jtitle><date>2023-02-01</date><risdate>2023</risdate><volume>15</volume><issue>3</issue><issn>1999-4923</issn><eissn>1999-4923</eissn><abstract>This study aims to prepare a novel breast cancer-targeted micelle-based nanocarrier, which is stable in circulation, allowing intracellular drug release, and to investigate its cytotoxicity, apoptosis, and cytostatic effects, in vitro. The shell part of the micelle is composed of zwitterionic sulfobetaine ((N-3-sulfopropyl-N,N-dimethylamonium)ethyl methacrylate), while the core part is formed by another block, consisting of AEMA (2-aminoethyl methacrylamide), DEGMA (di(ethylene glycol) methyl ether methacrylate), and a vinyl-functionalized, acid-sensitive cross-linker. Following this, a targeting agent (peptide (LTVSPWY) and antibody (Herceptin[sup.®] )), in varying amounts, were coupled to the micelles, and they were characterized by [sup.1] H NMR, FTIR (Fourier-transform infrared spectroscopy), Zetasizer, BCA protein assay, and fluorescence spectrophotometer. The cytotoxic, cytostatic, apoptotic, and genotoxic effects of doxorubicin-loaded micelles were investigated on SKBR-3 (human epidermal growth factor receptor 2 (HER2)-positive) and MCF10-A (HER2-negative). According to the results, peptide-carrying micelles showed a higher targeting efficiency and better cytostatic, apoptotic, and genotoxic activities than antibody-carrying and non-targeted micelles. Also, micelles masked the toxicity of naked DOX on healthy cells. In conclusion, this nanocarrier system has great potential to be used in different drug-targeting strategies, by changing targeting agents and drugs.</abstract><pub>MDPI AG</pub><doi>10.3390/pharmaceutics15030733</doi></addata></record>
fulltext fulltext
identifier ISSN: 1999-4923
ispartof Pharmaceutics, 2023-02, Vol.15 (3)
issn 1999-4923
1999-4923
language eng
recordid cdi_gale_infotracmisc_A743769713
source Publicly Available Content Database; PubMed Central (Training)
subjects Antibodies
Comparative analysis
Drug delivery systems
Drugs
Identification and classification
Materials
Micelles
Peptides
Vehicles
Viral antibodies
title HER2-Specific Peptide Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T22%3A28%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HER2-Specific%20Peptide%20Targeted%20Core%20Cross-Linked%20Micelles%20for%20Breast%20Cancer:%20A%20Comparative%20Study&rft.jtitle=Pharmaceutics&rft.au=Bayram,%20Nazende%20Nur&rft.date=2023-02-01&rft.volume=15&rft.issue=3&rft.issn=1999-4923&rft.eissn=1999-4923&rft_id=info:doi/10.3390/pharmaceutics15030733&rft_dat=%3Cgale%3EA743769713%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g673-a50830955072ebd71284e764430dd96cc5aa4fbaebd202ca3cd36d9d4141a9d13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A743769713&rfr_iscdi=true